All posts by carlos ibanez

A treasure trove for jazz lovers

Musica degradata

In its first year of existence, the music blog Musica degradata has already posted over 400 entries of rare live concerts and ripped vinyls from the whole spectrum of contemporary jazz. The blog is a special treat for ECM fans, as the posts include incredible performances from many of its artists during the golden years of the label. Most of the recordings have quite decent sound quality and can be downloaded through an external site. Well worth periodic visits and a subscription to its RSS feed.

Making science (part X): What open access journals have in common with premium wine

Open access journals charge fees to their authors for publication of accepted articles. Some of those fees can be quite significant. Cell Reports, a new  journal from Cell Press, charges $5,000 per article, the highest among open access research periodicals. There is currently a debate as to whether the journals that charge the most are the most influential. A recent survey appears to indicate that price doesn’t always buy prestige in open access. My friend and colleague M.F. has recently made a prescient comment in this context: “…but apart from the commercial desire to maximize profits, the pricing is probably designed as part of the brand signal, to make the point that this should be in the very top tier of journals. Similar to launching a new “premium” wine to the market, if price on release is low, the consumers will never perceive it as a premium wine… . Time will tell if this self-fulfilling prophecy is indeed true, or if journals like Open Biology or eLife can completely break that model. Read more...

Making science (part IX): The process of acceptance of scientific theories

Novel scientific propositions are initially taken with skepticism. Eventually, they become accepted –at least some of them. The transition between heressy and main stream has been debated ad nauseam. British geneticist J.B.S. Haldane (1892-1964) has been famous for many things, one among them was his incisive sarcasm. Haldane was an assiduous contributor to the Journal of Gentics, not only of scientific articles, but often many book reviews. One of those reviews, published in 1963 (Journal of Genetics Vol. 58, page 464), is perhaps the best known among the lot, not because of the book being reviewed, but because of Haldane’s now famous description of the stages in the process of acceptance of scientific theories. In Haldane’s words, theories invariably pass through “the “usual four stages”: Read more...

Making science (part VIII): A more specialized journal

“Dear Author, 

Thank you for sending us your paper “Downregulation of HlpxE-mediated transcription doubles median life-span expectancy in humans”, but I am afraid we cannot offer to publish it in The Current Biologist.

We appreciate the interest in the issue you are addressing, and your results sound potentially significant for the field, but our feeling is that at this stage your paper would be better suited to a somewhat more specialised journal.

I am sorry that we cannot give you a more positive response, but thank you for your interest in The Current Biologist.

Regards,
Geoffrey South
Editor”

Many of us —professional scientists writing research articles— have had to confront this type of letters from journal editors. We have grown accustomed to them. A standard cut-and-paste piece of text used knee-jerkedly by editors without much thought or consideration. We file them promptly, and move on. After all, there are plenty of journals around, both general and specialized. No big deal, right? Read more...

Making science (part VII): On the utility of science

In a recent interview for the podcast series of the Proceedings of the National Academy of Sciences of the USA, Ira Mellman of Genentech expressed his views on the utility of science practiced at academic institutions. After an academic career at Rockefeller and Yale University, Mellman joined Genentech in 2007 where he is Vice President of Research Oncology. Mellman is a member of the National Academy of Sciences since 2011. The interview is about current challenges in the field of cancer immunotherapy. But things get a bit more controversial at the end. Scroll the audio featured below to -0:35 and you’ll hear this:

PNAS: “I asked Mellman whether his move from academia to industry has brought him closer to his goal of practicing people-centered science.” Read more...